Home>Topics>>Risk And Reward Seem Pretty Balanced At Seattle Genetics
Risk And Reward Seem Pretty Balanced At Seattle Genetics
Healthcare Sector and Stocks Analysis from Seeking Alpha
Tue, 19 Aug 2014
By Stephen Simpson, CFA : Oncology biotechSeattle Genetics (NASDAQ: SGEN ) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on optimism for the company's deep portfolio of ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.